Home > Publications Database > Neurofilament light chain is a cerebrospinal fluid biomarker in hereditary spastic paraplegia. > print

001     157807
005     20230915092357.0
024 7 _ |a 10.1002/acn3.51358
|2 doi
024 7 _ |a pmid:33819388
|2 pmid
024 7 _ |a pmc:PMC8108414
|2 pmc
024 7 _ |a altmetric:103353475
|2 altmetric
037 _ _ |a DZNE-2021-01264
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Kessler, Christoph
|0 P:(DE-2719)9000957
|b 0
|e First author
|u dzne
245 _ _ |a Neurofilament light chain is a cerebrospinal fluid biomarker in hereditary spastic paraplegia.
260 _ _ |a Chichester [u.a.]
|c 2021
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1655724509_9505
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a CC BY-NC-ND
520 _ _ |a Despite the need for diagnostics and research, data on fluid biomarkers in hereditary spastic paraplegia (HSP) are scarce. We, therefore, explore Neurofilament light chain (NfL) levels in cerebrospinal fluid (CSF) of patients with hereditary spastic paraplegia and provide information on the influence of demographic factors.The study recruited 59 HSP cases (33 genetically confirmed) and 59 controls matched in age and sex. Neurofilament light chain levels were assessed by enzyme-linked immunosorbent assay. The statistical analysis included the effects of age, sex, and genetic status (confirmed vs. not confirmed).Levels of CSF NfL were significantly increased in patients with hereditary spastic paraplegia compared to controls (median 741 pg/mL vs. 387 pg/mL, p < 0.001). Age (1.4% annual increase) and male sex (81% increase) impacted CSF NfL levels in patients. The age-dependent increase of CSF NfL levels was steeper in controls (2.6% annual increase). Thus, the CSF NfL ratio of patients and matched controls-expressing patients' fold increases in CSF NfL-declined considerably with age.CSF NfL is a reliable cross-sectional biomarker in hereditary spastic paraplegia. Sex is a relevant factor to consider, as male patients have remarkably higher CSF NfL levels. While levels also increase with age, the gap between patients and controls is narrowing in older subjects. This indicates distinct temporal dynamics of CSF NfL in patients with hereditary spastic paraplegia, with a rise around phenotypic conversion and comparatively static levels afterward.
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 0
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 1
588 _ _ |a Dataset connected to DataCite
650 _ 2 |a Adolescent
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Age Factors
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Biomarkers: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Cross-Sectional Studies
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Neurofilament Proteins: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Sex Factors
|2 MeSH
650 _ 2 |a Spastic Paraplegia, Hereditary: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Spastic Paraplegia, Hereditary: diagnosis
|2 MeSH
650 _ 2 |a Young Adult
|2 MeSH
700 1 _ |a Serna-Higuita, Lina M
|b 1
700 1 _ |a Rattay, Tim W
|0 P:(DE-2719)2811827
|b 2
|u dzne
700 1 _ |a Maetzler, Walter
|0 P:(DE-2719)2810915
|b 3
|u dzne
700 1 _ |a Wurster, Isabel
|0 P:(DE-2719)2812736
|b 4
|u dzne
700 1 _ |a Hayer, Stefanie
|0 P:(DE-2719)2813263
|b 5
|u dzne
700 1 _ |a Wilke, Carlo
|0 P:(DE-2719)2814101
|b 6
|u dzne
700 1 _ |a Hengel, Holger
|0 P:(DE-2719)2811940
|b 7
|u dzne
700 1 _ |a Reichbauer, Jennifer
|0 P:(DE-2719)2812712
|b 8
|u dzne
700 1 _ |a Armbruster, Marcel
|b 9
700 1 _ |a Schöls, Ludger
|0 P:(DE-2719)2810795
|b 10
|u dzne
700 1 _ |a Martus, Peter
|b 11
700 1 _ |a Schüle-Freyer, Rebecca
|0 P:(DE-2719)2812018
|b 12
|e Last author
|u dzne
773 _ _ |a 10.1002/acn3.51358
|g Vol. 8, no. 5, p. 1122 - 1131
|0 PERI:(DE-600)2740696-9
|n 5
|p 1122 - 1131
|t Annals of Clinical and Translational Neurology
|v 8
|y 2021
|x 2328-9503
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/157807/files/DZNE-2021-01264.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/157807/files/DZNE-2021-01264.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:157807
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9000957
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2811827
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 3
|6 P:(DE-2719)2810915
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2812736
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)2813263
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)2814101
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)2811940
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)2812712
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)2810795
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 12
|6 P:(DE-2719)2812018
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 1
914 1 _ |y 2021
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-02-02
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-02-02
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2021-02-02
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2021-02-02
915 _ _ |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND (No Version)
|0 LIC:(DE-HGF)CCBYNCNDNV
|2 V:(DE-HGF)
|b DOAJ
|d 2021-02-02
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ANN CLIN TRANSL NEUR : 2021
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2021-04-16T15:13:11Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2021-04-16T15:13:11Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
|d 2021-04-16T15:13:11Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-09
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-09
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-09
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b ANN CLIN TRANSL NEUR : 2021
|d 2022-11-09
920 1 _ |0 I:(DE-2719)1210000
|k AG Gasser 1
|l Parkinson Genetics
|x 0
920 1 _ |0 I:(DE-2719)5000024
|k AG Maetzler
|l Functional Neurogeriatrics
|x 1
920 1 _ |0 I:(DE-2719)1240005
|k Core ICRU
|l Core ICRU
|x 2
920 1 _ |0 I:(DE-2719)1210001
|k AG Jucker
|l Cell Biology of Neurologic Diseases
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1210000
980 _ _ |a I:(DE-2719)5000024
980 _ _ |a I:(DE-2719)1240005
980 _ _ |a I:(DE-2719)1210001
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21